Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06509503

Impact of Combined Oral Contraceptive Pills on Migraine

Impact of Combined Oral Contraceptive Pills on Migraine, a Randomized Controlled Trial

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
400 (estimated)
Sponsor
Kafrelsheikh University · Academic / Other
Sex
Female
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

The investigators will assess the effect of combined oral contraceptive pills (COCs) on migraine features and treatment response to allow better interpretation of the exact consequence of hormonal contraceptive use on migraineurs.

Detailed description

The investigators will use a questionnaire to detect the migraineur demographic and clinical features (disease duration, attack frequency and duration, pain intensity assessed by visual analogic scale, HIT score in female patients on regular COCs * Special emphasis was put on clinical phenotype (for example, the character of pain, location, associated symptoms, etc.); vascular risk factors (hypertension, diabetes, smoking); history of cerebrovascular events and other conditions (collagen disorders, hepatic disorders, blood diseases, heart, kidneys), and family history. * All the patients will undergo clinical neurological and general physical examinations, and migraine history and associated phenotypic features will be established.

Conditions

Interventions

TypeNameDescription
DRUGCombined oral contraceptiveThe arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are regular users of COCs and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.
DRUGVaginal RingThe arm will include 200 migraine patients diagnosed according to ICHD3-beta criteria. The patients are users of mechanical contraceptive methods and will receive propranolol 80-160mg daily and ibuprofen 200-400 mg only in acute migraine attacks for 3 months.

Timeline

Start date
2024-07-15
Primary completion
2025-05-15
Completion
2025-07-30
First posted
2024-07-19
Last updated
2024-10-09

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT06509503. Inclusion in this directory is not an endorsement.